{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.671","value":"-20.42"},{"groupId":"OG001","spread":"10.318","value":"-21.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI:\n\nSDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 4 mg baricitinib (LY3009104) capsule or identical placebo capsule, orally once daily for 12 weeks in Part A received 4 mg baricitinib (LY3009104) and 1 placebo tablet orally once daily for 52 weeks in Part B.","id":"OG000","title":"Combined 4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy who were administered 1 mg, 2 mg, 8 mg baricitinib (LY3009104) capsules orally once daily for 12 weeks in Part A received 2 x 4 mg baricitinib (LY3009104) tablets orally once daily for 52 weeks in Part B.","id":"OG001","title":"Combined 8 mg Baricitinib (LY3009104)"}],"paramType":"MEAN","populationDescription":"All participants who received any amount of study drug in Part B and had data for SDAI at analysis time points. The last non-missing post-baseline value in Part B was used.","reportingStatus":"POSTED","timeFrame":"Baseline, 64 weeks","title":"Mean Change in SDAI Responses up to 64 Weeks (Part B)","type":"SECONDARY","unitOfMeasure":"units on a scale"}